PE Recovery 2026: Distribution Acceleration and Momentum Building in M&A Dealmaking

I watched a GP try to justify three years of zero distributions to his LPs in 2024. His deck was immaculate—147 slides, color-coded deal pipeline charts, market comps showing "paper gains" of 22%. By slide 89, someone finally asked the question everyone was thinking: "When do we actually see cash?"

The room went silent. The GP cleared his throat. "Market conditions remain challenging, but we're positioned for significant liquidity events in 2026."

Translation: We have no idea, but we need you to re-up for Fund IV.

That was eighteen months ago. Today, that same GP just distributed $340 million across two portfolio exits in Q1 2026. The difference? Private equity distributions are finally accelerating after three years of the deepest freeze in deal liquidity since the 2008 financial crisis.

According to Bain's 2026 Global Private Equity Report, M&A momentum is building across all major markets. Deal count is up 31% year-over-year. Exit multiples are recovering. And critically, dry powder deployment is accelerating as GPs who sat on their hands for 36 months finally have clearing prices that work.

For LPs evaluating entry points into private equity, this isn't just noise. This is the signal you've been waiting for—but only if you understand what's actually driving the recovery and how to position for the next 24 months of dealmaking.

Why PE Froze for Three Years (And What Changed)

The 2022-2024 private equity drought wasn't a mystery. It was math.

When the Federal Reserve raised rates from 0.25% to 5.25% in eighteen months, the entire PE playbook broke. Deals penciled at 3% debt suddenly needed 9% financing. Strategic buyers who would pay 14x EBITDA in 2021 were offering 8x in 2023. Portfolio companies that were "growing into their valuations" were shrinking out of them as consumers tightened spending.

GPs had three options: sell at a loss, hold and pray, or manufacture fake liquidity through continuation funds and NAV loans. Most chose option two. Distribution rates dropped 64% from 2021 to 2023, according to data from PitchBook. LPs who expected 12-15% annual distributions got 4% if they were lucky.

But something shifted in late 2025. Not sentiment. Not hope. Actual clearing prices.

The catalyst wasn't rate cuts—the Fed only dropped 50 basis points by year-end 2025. It was valuation recalibration. Buyers and sellers finally agreed on what companies were worth in a 5% cost-of-capital environment. Strategic acquirers resumed M&A activity as their own stock prices stabilized. And critically, the wall of maturing debt that everyone feared became a refinancing opportunity instead of a default wave.

By Q4 2025, deal volume was up 23% quarter-over-quarter. By Q1 2026, it was up another 18%. This isn't a blip. This is momentum.

The Distribution Wave: What GPs Are Actually Exiting

I talked to seven GPs in the past 90 days who are actively preparing exits. None of them are selling their "trophy assets." They're selling clean stories that don't require explanation.

One mid-market healthcare GP is exiting a dental services platform acquired in 2019 at 9.5x EBITDA. Current exit multiple: 11.2x. Not a home run, but a 2.8x cash-on-cash return after five years in a market that went sideways. The buyer? A strategic acquirer who sees consolidation opportunity and can finance at 7% instead of the 12% cost of capital the PE buyer would need.

Another GP is exiting a software business acquired in 2020—not because it's performing poorly, but because he can finally get fair value. Revenue grew 140% since acquisition. EBITDA margins expanded from 22% to 38%. But for three years, no buyer would pay what the business was worth. In Q1 2026, he got three credible bids above his target exit multiple.

This is what distribution acceleration actually looks like. It's not panic selling. It's GPs who have been sitting on mature assets finally finding buyers willing to pay clearing prices.

The sectors seeing the most exit activity? Healthcare services, B2B software, industrial automation, and specialty finance. The sectors still frozen? Consumer discretionary, commercial real estate, and anything that depends on low interest rates to pencil.

Dry Powder Deployment: $2.3 Trillion Looking for Deals

Here's the problem with three years of no distributions: LPs stopped committing to new funds.

Why would you commit another $50 million to Fund V when Fund III hasn't returned a dollar in 36 months? The denominator effect crushed LP allocation capacity. Pension funds that had 12% private equity allocations suddenly had 18% because public equities crashed and PE marks stayed artificially high.

But GPs kept raising. And raising. And raising. According to Preqin data, private equity firms are sitting on $2.3 trillion in dry powder as of Q1 2026—the highest level ever recorded.

That money doesn't sit forever. It has deployment deadlines. Most funds have 3-5 year investment periods. Funds raised in 2021 and 2022 are under pressure to put capital to work or start returning it to LPs.

This is why M&A momentum is building. It's not because deals suddenly got easier. It's because GPs have no choice but to deploy.

I talked to a lower-mid-market GP last month who raised $380 million in 2022. Two years later, he's deployed $87 million—23% of the fund. His LPs are asking questions. His management fees are under scrutiny. And his Fund II fundraise depends on showing he can actually put money to work.

So what's he doing? Writing smaller checks at higher valuations than he'd prefer. Because doing deals at 11x EBITDA is better than sitting on cash and losing credibility with LPs.

This is the reality of 2026 PE. The discipline of 2023 is giving way to the deployment pressure of 2026. For sellers, that's opportunity. For LPs evaluating entry points, that's risk.

LP Strategy: Where to Enter the Recovery

If you're an LP evaluating private equity allocations in 2026, you're staring at a binary decision: jump in now while distributions are accelerating, or wait for the next correction.

The case for entering now:

• Distribution rates are improving — Q1 2026 distributions were up 47% year-over-year, according to Bain. GPs are finally returning cash.
• Secondary market pricing is attractive — You can buy into existing funds at 85-92 cents on the dollar as some LPs liquidate to rebalance portfolios.
• Deployment risk is front-loaded — Funds raising now will deploy into 2027-2029, after valuations normalize further.
• The J-curve is compressing — Deals closing in 2026 should see liquidity by 2029-2031, not the traditional 7-10 year hold periods.

The case for waiting:

• Valuations are still elevated — Median buyout multiple is 11.4x EBITDA, down from 12.8x in 2021 but above the 20-year average of 10.2x.
• Deployment pressure creates bad deals — GPs under pressure to deploy capital make compromises on quality and price.
• Recession risk is non-zero — If the economy tips into recession in late 2026 or 2027, distributions will freeze again.
• Fee pressure is building — LPs are negotiating lower management fees and higher hurdle rates, which changes fund economics.

My take? Enter selectively, not broadly.

If you're allocating to PE in 2026, focus on three things:

1. GPs with strong distribution track records in down markets. Don't just look at IRR. Look at DPI (distributions to paid-in capital). A GP who distributed capital in 2023 and 2024 has proven they can find exits when others can't.

2. Sectors with structural tailwinds, not cyclical recovery plays. Healthcare services will grow regardless of GDP. B2B software with mission-critical use cases will retain and expand. Industrial automation benefits from labor shortages. Consumer discretionary? Hard pass.

3. Funds with 60%+ deployment already completed. Entering a fund that's 60% deployed means you're buying into known assets at known valuations, not hoping the GP makes smart decisions in an overheated market.

And if you're sophisticated enough, the secondary market is where the real opportunity is. Buying LP stakes in 2019-2021 vintage funds at 88 cents on the dollar gives you exposure to mature assets nearing exit—without the deployment risk of a new fund.

What Happens Next: The 2026-2028 Exit Cycle

Here's what I'm watching for the next 24 months:

Exit volume will increase 40-60% in 2026 vs. 2025. GPs who held assets for 6-8 years instead of the traditional 4-6 are finally exiting. That backlog creates a wave of liquidity for LPs who have been starved for distributions.

Strategic buyers will dominate M&A. Financial buyers (other PE firms) are sitting on expensive debt and facing deployment pressure themselves. Strategic acquirers with strong balance sheets and cheap internal cost of capital will win the best assets. For GPs, that means exit multiples will compress slightly as the "financial engineering premium" disappears.

Continuation funds will become standard. GPs with trophy assets that aren't ready to sell will offer LPs liquidity through continuation funds—selling the asset from Fund III to Fund IV with new LPs buying in. This is controversial, but it's becoming the primary liquidity mechanism for top-quartile assets.

Fundraising will remain bifurcated. Top-quartile GPs with strong distribution records will raise at or above target. Everyone else will struggle, take longer, and accept lower fees. The "barbell strategy" is real—LPs are concentrating capital with proven winners and cutting off the middle-tier managers.

Final Takeaways: How to Think About PE Allocations Now

The private equity recovery is real, but it's not uniform. Distribution acceleration is happening for GPs with the right assets in the right sectors. M&A momentum is building as dry powder gets deployed and exit windows reopen.

But this isn't 2021. Valuations are higher than historical averages. Leverage is more expensive. Growth assumptions are more conservative. And LPs have learned that paper gains don't pay distributions.

If you're evaluating PE allocations in 2026, here's what matters:

• Focus on distribution track record, not IRR promises. Cash returned matters more than mark-to-market gains.
• Enter through secondaries or 60%+ deployed funds to reduce deployment risk in an expensive market.
• Favor sectors with structural tailwinds — healthcare, B2B software, industrial automation.
• Demand better terms — lower management fees, higher hurdle rates, more GP co-investment.
• Don't chase recovery plays — consumer discretionary and commercial real estate are value traps.

The PE recovery is gaining traction. But traction isn't the same as momentum. And momentum isn't the same as returns.

Position accordingly.

Ready to connect with private equity investors who understand market cycles and deploy capital strategically? Apply to join Angel Investors Network — where sophisticated LPs and GPs share deal flow, market intelligence, and capital deployment strategies that work in any environment.